Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Major Depression Moderate Clear all
Recruiting Not applicable Interventional

Telehealth Behavioral Activation for Teens

NCT06273995
View directory record Official record
Conditions
Depression, Suicide and Self-harm, Depression in Adolescence, Depression Mild, Depression Moderate, Depression Severe
Interventions
Behavioral Activation
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of AGO178 in Participants With Liver Impairment

NCT01531309
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AGO178
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 10:53 AM EDT
Recruiting Not applicable Interventional

Treating Major Depression With Yoga Mono-therapy

NCT06091527
View directory record Official record
Conditions
Depression Mild, Depression Moderate
Interventions
Yoga practice, Education
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

NCT01312922
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
Drug
Lead sponsor
PharmaNeuroBoost N.V.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Glendale, California • National City, California • Riverside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

NCT00621946
View directory record Official record
Conditions
Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 23, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kintsugi Voice Device Pivotal Study

NCT06809907
View directory record Official record
Conditions
Depression, Depression Moderate, Depression Severe, Depression Mild
Interventions
Kintsugi Voice Device
Device
Lead sponsor
Kintsugi Mindful Wellness, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Completed No phase listed Observational

Combining Data Sources to Identify Effect Moderation for Personalized Mental Health

NCT05267873
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Duloxetine, Vortioxetine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 65 Years
Enrollment
9,586 participants
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Clinical Outcomes of a Digital Mental Health Intervention for Moderate/Severe Depression and Anxiety

NCT07081061
View directory record Official record
Conditions
Depression, Anxiety, Mental Health Issue, Mental Health Wellness 2
Interventions
BetterHelp
Other
Lead sponsor
Teladoc Health
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

MRS and Medication Response: A Pilot Study

NCT03254342
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild, Major Depression Moderate, Major Depression Severe
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 23, 2026, 10:53 AM EDT
Terminated Phase 3 Interventional

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 4 Interventional

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

NCT00208715
View directory record Official record
Conditions
Major Depression, Mental Health
Interventions
Provigil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Stanford, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
51
States / cities
Birmingham, Alabama • Lafayette, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

KET-RO Plus RO DBT for Treatment Resistant Depression

NCT06138691
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine Infusion plus RO DBT
Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

Effects Of Antidepressants On Sexual Functioning In Adults

NCT00051272
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 23, 2026, 10:53 AM EDT
Terminated Not applicable Interventional Results available

Study of Respiratory Depression When Using a Hydromorphone Pain Protocol

NCT01784991
View directory record Official record
Conditions
Pain, Respiratory Depression
Interventions
Hydromorphone, Usual care group
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
60 Years to 90 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

NCT03307070
View directory record Official record
Conditions
Major Depressive Disorder, Traumatic Brain Injury
Interventions
Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 23, 2026, 10:53 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression

NCT04211467
View directory record Official record
Conditions
Depression, Clinical Depression, Depression, Anxiety, Depression, Postpartum, Depression, Endogenous, Depression in Remission, Depression Chronic, Depression Moderate, Depression Severe
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Practical Application of Accelerated iTBS for MDD

NCT06113575
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe, Major Depressive Disorder, Recurrent, Moderate
Interventions
NeuroStar TMS
Device
Lead sponsor
Sonder Behavioral Health and Wellness
Other
Eligibility
22 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

Effects of Antidepressants on Sexual Functioning

NCT00051259
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-Release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 23, 2026, 10:53 AM EDT
Not yet recruiting Phase 1 Interventional

Shortened LSD Intervention for Major Depressive Disorder

NCT07503002
View directory record Official record
Conditions
Major Depression Moderate, Major Depression Severe, Major Depression
Interventions
LSD, Risperidone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

NCT03000530
View directory record Official record
Conditions
Major Depression
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Garden Grove, California • Orlando, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

NCT00566202
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Escitalopram, JNJ-18038683
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 23, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
46
States / cities
Tucson, Arizona • Anaheim, California • Culver City, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 10:53 AM EDT